No Data
No Data
Express News | Glaxosmithkline Sues Moderna for U.S. Patent Infringement Over Mrna Technology in Covid-19 Vaccines - Court Filing
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Gritstone Oncology (GRTS) and Immutep (IMMP)
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK Says ANCHOR Trials for Depemokimab Met Primary Endpoints
Stocks to Watch Monday: Tesla, Boeing, Vulcan Materials, GSK -- WSJ
glaxosmithkline (GSK.US) experimental drug Depemokimab for the treatment of rhinitis trial achieved positive results
An experimental drug developed by GlaxoSmithKline for the treatment of a common type of rhinitis has shown positive results in two late-stage trials, which has boosted the research and development pipeline of this united kingdom pharmaceutical company.